Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

Nature Reviews Cancer 16, 275 (2016).
doi:10.1038/nrc.2016.36

Authors: Suzanne L. Topalian, Janis M. Taube, Robert A. Anders & Drew M. Pardoll
With recent approvals for multiple therapeutic antibodies that block cytotoxic T lymphocyte associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) in melanoma, non-small-cell lung cancer and kidney cancer, and additional immune checkpoints being targeted clinically, many questions still remain regarding the optimal

Source: Nature Reviews Cancer - April 14, 2016 Category: Cancer & Oncology Authors: Suzanne L. TopalianJanis M. TaubeRobert A. AndersDrew M. Pardoll Tags: Review Source Type: research